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Abstract
Objectives To compare the predictive performance and
potential clinical usefulness of risk calculators of the European
Randomized Study of Screening for Prostate Cancer (ERSPC
RC) with and without information on prostate volume.
Methods We studied 6 cohorts (5 European and 1 US) with
a total of 15,300 men, all biopsied and with pre-biopsy TRUS
measurements of prostate volume. Volume was categorized
into 3 categories (25, 40, and 60 cc), to reflect use of digital
rectal examination (DRE) for volume assessment. Risks of
prostate cancer were calculated according to a ERSPC DRE-
based RC (including PSA, DRE, prior biopsy, and prostate
volume) and a PSA ? DRE model (including PSA, DRE,
and prior biopsy). Missing data on prostate volume were
completed by single imputation. Risk predictions were
evaluated with respect to calibration (graphically), discrim-
ination (AUC curve), and clinical usefulness (net benefit,
graphically assessed in decision curves).
Results The AUCs of the ERSPC DRE-based RC ranged
from 0.61 to 0.77 and were substantially larger than the
AUCs of a model based on only PSA ? DRE (ranging
from 0.56 to 0.72) in each of the 6 cohorts. The ERSPC
DRE-based RC provided net benefit over performing a
prostate biopsy on the basis of PSA and DRE outcome in
five of the six cohorts.
Conclusions Identifying men at increased risk for having
a biopsy detectable prostate cancer should consider multi-
ple factors, including an estimate of prostate volume.
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Introduction
Although screening for prostate cancer (PC) can reduce
disease-specific mortality [1–3], key problems are over
diagnosis and unnecessary testing (i.e., prostate biopsies).
Applying a purely PSA-based biopsy indication
(PSA C 3.0 ng/ml as indication for prostate biopsy)
resulted in 76% of biopsies being performed in men who
were found not to have cancer on that biopsy [2].
Increasing the PSA threshold above which men are rec-
ommended to undergo a biopsy causes a considerable
number of cancers to be missed [4]. A more promising
approach is to refine the biopsy indication based on the
multivariable combination of PSA with other patient and
disease characteristics [5].
We previously developed a multistep PC risk calcula-
tor based on data from the European Randomized Study
of Screening for Prostate Cancer (ERSPC) Rotterdam
(http://www.prostatecancer-riskcalculator.com). The cal-
culator is meant as a decision aid for lay people (RC#1),
general practitioners (RC#2), and urologists (RC#3 for
men previously unscreened, RC#4 for men with a previ-
ous PSA test, RC#5 for men with a previous negative
biopsy, and RC#6 to predict indolent PC) by providing
individualized estimates of the risk of detecting PC on
biopsy [6, 7].
The calculators have some limitations (i.e., based on
sextant biopsy information), but have been validated in
several cohorts with satisfactory results [8–10]. Clinical
implementation may however be hampered by the need to
perform a TRUS before biopsy. We therefore developed
variants of the original calculators without the need for
TRUS measurements. Next to PSA and DRE outcome
(abnormal vs. normal), the DRE can also estimate prostate
volume and may hence avoid the need for TRUS before
biopsy [11].
We aimed to test the validity of the DRE-based volume
ERSPC risk calculator and to compare its performance to a
biopsy strategy based on the PSA value and the outcome of
the DRE (i.e., abnormal vs. normal with no information on
prostate volume included in the risk prediction).
Patients and methods
Patients
Data were from the Prostate Biopsy Collaborative Group,
which includes ten European and US cohorts as previously
described [12]. We excluded 4 cohorts where prostate
volume was not available, leaving 6 cohorts with a total of
15,300 men for analysis. These included four screening
cohorts from the ERSPC: Go¨teborg, Sweden Round 1
screening (GOTEBORG-R1), Go¨teborg Rounds 2–6
(GOTEBORG-R2–6), Rotterdam, the Netherlands, Round
1 (PSA C3.0 ng/ml) (ROTTERDAM-R1), Rotterdam
Rounds 2–3 (ROTTERDAM-R2–3); one other screening
cohort (Tyrol, Austria) (TYROL); and one US clinical
cohort [Cleveland Clinic, Ohio (CCF)]. Biopsy decisions
for all ERSPC cohorts were indicated by PSA C3 ng/ml
(4 ng/ml for Rotterdam during some years) and for the
other cohorts by clinical indication typically an elevated
PSA without strict protocol. Biopsy schemes for all ERSPC
cohorts were 6-core, for CCF, greater than 8-core, Tyrol 6,
10, or 12 depending on year. All cohorts except for
GOTEBORG-R1 and ROTTERDAM-R1 included some
men who had been previously screened. Biopsies after a
positive biopsy for PC were excluded from the analysis.
Methods
The ERSPC DRE-based volume calculators were devel-
oped on a cohort of 3,624 men who had never before had a
biopsy (DREvol-RC3) and a cohort of men (N = 2,896)
previously screened/biopsied (DREvol-RC4/5) [11]. The
model based on PSA and DRE outcome only was devel-
oped on similar cohorts resulting in a model suitable for
men previously unscreened (PSADRE-model) and men
previously screened and/or biopsied (PSADRE-model, see
‘‘Appendix’’ for formulas). Characteristics of each cohort
were summarized by descriptive statistics. For each biopsy
in the dataset, risks were computed using the DREvol-RC3
(men not previously biopsied) or DREvolRC4/5 (men
previously biopsied) [11] as well as the model based on
PSA and DRE alone (PSADRE-model) and compared to
the outcome of presence of cancer at biopsy. Missing
values were imputed (filled in) based on correlations
between any of the predictor variables and correlations
with the end point. A single imputation was performed,
using the first set of imputed values from a multiple
imputation procedure (aregImpute, as implemented in R v
2.10.1 software) [13].
Since no data on prostate volume as assessed with DRE
were available in the validation cohorts, TRUS-assessed
prostate volume was recoded as in [11] into three volume
classes as can be estimated by DRE. TRUS-assessed vol-
umes \30 cc were recoded as 25 cc, volumes between 30
and 50 cc as 40 cc, and volumes C50 cc as 60 cc.
The predictive performance was evaluated by validation
plots, comparing the frequency of observed outcome to
predicted risks [14]. Perfect calibration results in a 45 line
of a loess smoother in this plot. The calibration slope
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should be 1, with values below 1 indicating too extreme
predictions, as might result from overfitting [13].
The discriminative ability of predictions is reflected in
the spread of the predictions, stratified by the presence of
cancer at biopsy. The area under the ROC curve (AUC,
equivalent to c statistic) summarized discriminative ability,
with pairwise testing by the DeLong test.
The clinical usefulness of the calculators was evaluated
by decision curves [15].
We focused on the range from 10 to 40% for the deci-
sion threshold. This is a reasonable range of thresholds
since some patients might opt for biopsy with a chance
cancer of 10% while few patients would refuse biopsy if
their risk was greater than 1 in 2–3.
Results
Study population
Median age ranged from 61 to 67 years and median PSA
levels from 3.5 to 5.8 ng/ml. The percentage of men with
an abnormal DRE result ranged from 10 to 26% in the
screening cohorts and was remarkably lower in the clinical
cohort where only 6% of the men had an abnormal DRE.
The missing data on prostate volume ranged from 0.4 to
30%. Despite the fact that two of the ERSPC cohorts and
the Tyrol-cohort included men who were previously
screened and/or biopsied, the cancer detection rates in the
screening cohorts were similar (26–28%, Table 1).
Table 1 Descriptives of the 6 validation cohorts
Goteborg
round 1
Goteborg
rounds 2–6
Rotterdam
round 1
Rotterdam
rounds 2–3
Cleveland
clinic
Tyrol
Number of patients 740 1,241 2,895 1,494 2,631 4,199
Number of biopsies 740 1,241 2,895 1,494 3,286 5,644
Age
Median (range) 61 (51, 70) 63 (53, 71) 66 (55, 75) 67 (59, 75) 64 (50, 75) 63 (50, 75)
PSA median (range) 4.7 (0.5, 226.0) 3.6 (2.0, 88.8) 5.0 (0.0, 245.0)a 3.5 (0.4, 99.5) 5.8 (0.2, 491.7) 4.2 (0.1, 3,210.0)
DRE result
Normal 614 (83%) 1,117 (90%) 2,137 (74%) 1,182 (79%) 3,083 (94%) 5,076 (90%)
Abnormal 126 (17%) 124 (10%) 758 (26%) 312 (21%) 203 (6%) 568 (10%)
Unknown 0 0 0 0 0 0
Prostate volume
Median (range) 44 (12–241) 40 (3–131) 51 (5–239) 46 (15–130) 42 (0–737) 40 (7–652)
Unknown (N, %) 7 (0.9) 274 (22.1) 13 (0.4) 7 (0.5) 986 (30.0) 476 (8.4)
Family history
No 0 0 1,708 (59%) 875 (59%) 1,690 (51%) 0
Yes 0 0 328 (11%) 160 (11%) 373 (11%) 0
Unknown 740 (100%) 1,241 (100%) 859 (30%) 459 (31%) 1,223 (37%) 5,644 (100%)
African origin
No 0 0 0 0 2,818 (86%) 0
Yes 0 0 0 0 422 (13%) 0
Unknown 740 (100%) 1,241 (100%) 2,895 (100%) 1,494 (100%) 46 (1%) 5,644 (100%)
Prior biopsy
Yes 0 0 0 0 1,091 (33%) 1,555 (28%)
No 740 (100%) 1,241 (100%) 2,895 (100%) 1,494 (100%) 2,195 (67%) 4,089 (72%)
Unknown 0 0 0 0 0 0
Cancer 192 (26%) 322 (26%) 800 (28%) 388 (26%) 1,292 (39%) 1,562 (28%)
Biopsy Gleason grade
B6 152 (79%) 269 (84%) 508 (64%) 297 (77%) 669 (52%) 911 (58%)
7 33 (17%) 45 (14%) 234 (29%) 78 (20%) 478 (37%) 319 (20%)
C8 7 (4%) 8 (2%) 52 (6%) 13 (3%) 145 (11%) 137 (9%)
Unknown 0 0 6 (1%) 0 0 195 (12%)
a PSA values were re-measured at the laboratory of Prof. Lilja in NY resulting in PSA levels \3.0 ng/ml
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Discrimination
In all validation cohorts, the AUC of the DREvol-RC
was larger than that of the PSADRE-model (each pair
wise comparison: p \ 0.001). In the strictly protocol-
based screening cohorts of the ERSPC centers, the
AUCs for the DREvol-RC and PSADRE-model were
0.776 (0.735–0.816) and 0.719 (0.673–0.764) for
GOTEBORG-R1; 0.609 (0.573–0.646) and 0.563
(0.525–0.601) for GOTEBORG-R2–6; 0.746 (0.724–
0.715) for ROTTERDAM-R1; and 0.659 (0.628–0.690)
and 0.606 (0.571–0.638) for ROTTERDAM-R2–3,
respectively. Hence, the improvement in AUC by using
the DREvol-RC versus the PSADRE-model was
approximately 0.05, although we note that Rotterdam
R1 is part of the development cohort and hence a
likely optimistic validation. In the two large, not
ERSPC validation cohorts, the differences in AUCs of
the DREvol-RC and the PSADRE-model were similar:
for the CCF cohort, the AUCs were 0.665 (0.646–
0.684) versus 0.620 (0.600–0.640) and for the Tyrol-
cohort 0.720 (0.705–0.735) versus 0.675 (0.659–
0.690).
Calibration
As expected, the calibration of the DREvol-RC was very good
for the ROTTERDAM-R1 cohort (Fig. 1). The validation
cohort ROTTERDAM-R2–3 differs from the development
cohort in that men with previous negative biopsy were
included in the development but not in the validation cohort,
and results from round 3 were included only in the validation
but not the development cohort. Yet, the validation plot
showed good calibration with a calibration slope close to 1
(0.96). Calibration in the large (intercept of 0.20) indicates
minor underprediction of cancer at biopsy. Calibration was
also satisfactory for the GOTEBORG-R1 and GOTEBORG-
R2–6 cohorts, but with some over prediction for probabilities
above 40%. In the large, screening-based Tyrol-cohort, minor
underprediction was noted. In the clinically derived CCF
cohort, a considerable underprediction was noted, especially
in the risk range below 50% (Fig. 1).
Net benefit
The DREvol-RC provided a net benefit over performing a
prostate biopsy in every men and performing a prostate
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Fig. 1 Calibration plots for the DRE-based ERSPC RC
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biopsy on the basis of PSA and DRE for threshold proba-
bilities of approximately 10% or higher in the cohorts
representing men screened for the first time (GOTEBORG
and ROTTERDAM-R1) and the Tyrol-cohort (Fig. 2).
Net benefit over performing a prostate biopsy in all men in
GOTEBORG-R2–6 and ROTTERDAM-R2–3) was less
but nevertheless present for risk thresholds between 25 and
40%. Ignoring information on prostate volume decreased
net benefit slightly. The net benefit curve for CCF suffers
from the observed underprediction, with a net benefit only
for higher thresholds ([35%), while the net benefit curves
on the Tyrol-cohort clearly show the additional value of
(a) a multivariable approach (PSA ? DRE) and (b) the
inclusion of information on prostate volume.
Discussion
A key measure for a prediction model is its ability to dis-
tinguish those who will have a biopsy detectable PC from
those who will not. In the ideal situation, this will lead to
biopsy only in those men that indeed have PC and hence
making the prostate biopsy a procedure to assess disease
aggressiveness.
The recently developed DREvol-RC was previously
validated in men screened at repeat screening rounds of
ERSPC Rotterdam (4th and 5th screening round) [11],
showing that volume estimation by DRE underestimated
the TRUS-assessed prostate volume. However, the median
values of the TRUS-assessed prostate volume (26.5, 45.6,
and 69.3 cc) were close to the three predefined volume
classes of 25, 40, and 60 cc, respectively. Since the sample
size of the validation cohort in [11] was relatively small,
additional studies are needed. This study performed a
validation of this DREvol-RC in six different cohorts, both
of screening and clinical origin. The AUCs covered a wide
range (from 0.61 to 0.78), which reflects both the fit of the
prediction model to the cohort and the varying case-mix.
Higher AUC values will be found in more heterogeneous
cohorts [16]. In all cohorts, AUC values were substantially
larger than found for the model based on PSA and DRE
alone (PSADRE-model). This was also true for the two
largest validation cohorts, i.e., the Tyrol screening cohort
and the clinical CCF cohort.
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Fig. 2 Net benefit curves for the DRE-based ERSPC RC (large dashed black) versus the screening strategies of referring no men to biopsy
(horizontal line at 0), referring all men to biopsy (solid black) and referring men on the basis of PSA ? DRE (small dashed black)
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Better discrimination does not automatically imply
better clinical usefulness. A better discriminatory model
can suffer from major under or over prediction making it in
fact a dangerous tool to use in clinical decision making. In
the current study, the DREvol-RC was well calibrated
with the exception of the CCF cohort where a systematic
underprediction was observed. Baseline data of the CCF
cohort did not indicate it as a high risk cohort. The cancer
detection rate was however considerably higher (39%) as
compared to the other cohorts. This most likely is the result
of the biopsy procedure comprising of at least 10 cores or
more while the ERSPC RCs were based on sextant biop-
sies. Moreover, men who were actually biopsied in the
CCF cohort were preselected based on clinical judgment.
Biopsy may have been avoided in men with elevated PSA
levels due to the presence of BPH. This idea is supported
by the larger net benefit when using the DREvol-RC in
cohorts where men were biopsied purely based on an ele-
vated PSA level. Application of the DREvol-RC in clinical
cohorts hence needs further study, and a correction for the
miscalibration might need to be made.
Similar analysis for the Prostate Cancer Prevention Trial
(PCPT) RC [17, 18] (including PSA, DRE outcome, age,
and family history) shows limited to no clinical benefit as
compared to the policy of biopsying all men. These dif-
ferences in predictive performance have been observed in
previous studies [8, 9, 19]. Prostate volume was highly
predictive in a screening-based validation cohort of 525
men [9]. While prostate volume is lacking in the PCPT RC,
it is crucial within the ERSPC RCs. The predictors PSA
and prostate volume play an opposing role [6, 7, 20]: high
PSA level is positively related to PC at biopsy, but a large
prostate volume has a negative relation. Indeed, prostate
volume is related to serum PSA in men with Benign
prostatic hyperplasia and no evidence of PC, and the
relationship depends on age [21, 22]. In middle-aged men,
BPH may hence explain a high PSA. Histologically, dis-
tinguishable BPH is present in about 8% of men aged
31–40 years, and this prevalence increases markedly with
age to about 70% by the seventh decade of life [23].
In conclusion, identifying men at increased risk for
having a biopsy detectable PCa should consider multiple
factors. Prostate volume is a key element in such risk
prediction, and approximate estimation through DRE might
enable a more widespread use of this calculator.
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Appendix: Formulas used to calculate volume classes
and the DRE ERSPC RC risks [11]
Volume classes:
if (TRUS volume \ 30.0) volumeclasses = 25.
if (TRUS volume C 30.0 and TRUS volume \ 50)
volumeclasses = 40.
if (TRUS volume C 50) volumeclasses = 60.
Model on the basis of PSA and DRE for men not
previously biopsied:
If (priorscreening = 0) lpPSADREriskcalc3 = -1.743 ?
0.788 9 (log2 (PSA1) - 2.0) ? 1.105 9 (DRE1).
Model on the basis of PSA and DRE for men previ-
ously biopsied:
If (priorscreening = 1) lpPSADREriskcalc45 = -1.315 -
0.899 9 prevbiopsy ? (0.421 - 0.362 9 prevbiopsy) 9
(log2(PSA) - 2) ? (0.726 9 DRE).
DRE-based volume ERSPC Riskcalculator for men not
previously screened (DREvol-RC #3):
if (priorscreening = 0) lpDRE_ERSPC_riskcalc =
-1.826 ? 1.024 9 (log2(PSA) - 2.0) - 1.50 9 (log2
(volumeclasses)/lg10(2)) - 5.4) ? 0.992 9 (DRE).
DRE ERSPC Riskcalculator for men previously
screened and/or biopsied (DREvol-RC #45)
if (priorscreening [0) lpDRE_ERSPC_riskcalc = -1.470
- 0.677 9 priorbiopsy ? (0.576 - 0.423 9 priorbiopsy)
9 (log2(PSA) - 2) - 1.043 9 (log2(volumeclasses) -
5.5) ? (0.68 9 DRE).
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Log2 denotes the 2 log, which can also be calculated as
log(x)/log(2), with x = PSA (in ng/ml) or x = volume in
3 classes (25, 40, or 60). DRE denotes a positive DRE
examination (coded 0/1), prevbiosy denotes a previous
biopsy (coded 0/1).
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